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Tumor cells display on their surface several molecular chap-
erones that normally reside in the endoplasmic reticulum.
Because this display is unique to cancer cells, these chaperones
are attractive targets for drug development. Previous epitope-
mapping of autoantibodies (AutoAbs) from prostate cancer
patients identified the 78-kDa glucose-regulated protein (GRP78)
as one such target. Although we previously showed that anti-
GRP78 AutoAbs increase tissue factor (TF) procoagulant activ-
ity on the surface of tumor cells, the direct effect of TF activation
on tumor growthwasnot examined. In this study,we explore the
interplay between the AutoAbs against cell surface–associated
GRP78, TF expression/activity, and prostate cancer progres-
sion. First, we show that tumor GRP78 expression correlates
with disease stage and that anti-GRP78 AutoAb levels parallel
prostate-specific antigen concentrations in patient-derived
serum samples. Second, we demonstrate that these anti-GRP78
AutoAbs target cell-surface GRP78, activating the unfolded
protein response and inducing tumor cell proliferation through
a TF-dependent mechanism, a specific effect reversed by neu-
tralization or immunodepletion of the AutoAb pool. Finally,
these AutoAbs enhance tumor growth in mice bearing human
prostate cancer xenografts, and heparin derivatives specifically
abrogate this effect by blocking AutoAb binding to cell-surface
GRP78 and decreasing TF expression/activity. Together, these
results establish a molecular mechanism in which AutoAbs
against cell-surface GRP78 drive TF-mediated tumor progres-
sion in an experimental model of prostate cancer. Heparin
derivatives counteract this mechanism and, as such, represent
potentially appealing compounds to be evaluated in well-de-
signed translational clinical trials.
Prostate cancer is the most frequent malignant tumor in
men, whose age-adjusted incidence rates have dramatically
increased with the introduction of serum PSA2 screening and
early detection (1). Although patients with organ-confined dis-
ease may have a more favorable prognosis, metastatic disease
remains incurable. Secondary thrombotic complications can
increase morbidity and mortality in cancer patients. Several
lines of evidence demonstrate that such thrombogenic events
occur at the surface of tumor cells and involve an enhanced
expression and procoagulant activity of TF (2). In addition to its
critical role in hemostasis and blood clot formation, a growing
body of genetic and pharmacological investigation indicates
that tumor cell-expressed TF contributes to tumor growth via
an array of proangiogenic and immunomodulating cytokines,
chemokines, and growth factors (3).
GRP78 has long been established as an endoplasmic reticu-
lum (ER)-resident stress-response chaperone that facilitates
the correct folding and assembly of newly synthesized proteins
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(4). However, over the past decade, several studies demon-
strated that, when present on the surface of cancer cells, GRP78
also functions as a signaling receptor (5); for instance, the
binding of 2-macroglobulin to prostate cancer cells through
csGRP78 triggers insulin-like responses (6) and regulates tran-
scriptional activation of c-MYC target genes (7) to promote
tumor proliferation and survival (8). In summary, the atypical
presence of functional GRP78 “moonlighting” (9) at the tumor
cell surface has unambiguously been confirmed by many inde-
pendent reports as part of the UPR (reviewed in Ref. 10). Since
the first report of GRP78 translocation on the external side of
the cell (11) and the presence of circulating GRP78-targeting
AutoAbs (12, 13), csGRP78-targeted theranostic applications
have been validated in a wide variety of human tumors, includ-
ing prostate (14, 15), breast (16, 17), ovarian (18), and brain (19)
cancer, along with melanoma (20), leukemias, and lymphomas
(21, 49).
In previous collective work, by epitope-mapping (“finger-
printing”) the circulating repertoire of AutoAbs in prostate
cancer patients, we identified the consensusmotif CNVSDKSC
(12) as a specifically recognized epitope that corresponds to an
N-terminal domain (Leu98–Leu115) of GRP78 (22). This immu-
nogenic portion of GRP78 is also a functional binding site for
2-macroglobulin at the cell surface (23, 24). In addition, we
elucidated the mechanism whereby AutoAbs against cell-sur-
face GRP78 modulate TF activity via release of Ca2 from the
ER into the cytosol (25). All of these data indicate that binding
of the AutoAbs to GRP78 at the cell surface elicits multiple
signal transduction responses with a functional role in cancer.
Consistent with these observations, we have shown that men
with prostate cancer may have12-fold higher serum levels of
anti-GRP78 AutoAbs than age-matched cancer-free men,
which correlates with metastatic disease and, ultimately, with a
decreased overall survival (22).
Herewehave used a xenograftmousemodel of humanprostate
cancer to investigate the dependence on TF of tumor growth
potentiation by anti-GRP78 AutoAbs. Given that these AutoAbs
recognize an epitope on csGRP78 that overlaps with its heparin-
binding domain (22), we also evaluate and validate a low-molecu-
lar weight heparin (LMWH), enoxaparin, as a potential inhibitor
of tumorprogression.Together, the results presented in this study
show that the humoral anti-GRP78 AutoAb response is a viable
therapeutic target in experimental models, with perspective
potential application in patients with prostate cancer.
Figure 1. Prostate cancer grade correlateswithGRP78 expression and anti-GRP78AutoAb titers. A, specimens fromprostate cancer patients stained for
GRP78 were graded pathologically. Scale bar, 100 m. Top, grade 1: limited numbers of GRP78-positive cells. Middle, grade 2: increased numbers of GRP78-
positive cells.Bottom, grade4: highpositivity forGRP78. ExpressionofGRP78 is accompaniedbyprotein “moonlighting” andpresenceon the tumor cell surface
(representative cells are indicated by red arrows). B, anti-GRP78 AutoAb titers correlate with serum PSA concentrations in patients with prostate cancer, as
evaluated by Pearson correlation (p 0.05, r 38.4%, n 48). C, patients grouped in low (1–2 ng/ml, n 12), medium PSA (3–7 ng/ml, n 14), high (8–19
ng/ml, n  13), or very high (20 ng/ml, n  8) PSA levels show progressively increasing levels of anti-GRP78 AutoAb titers. Controls were age-matched
individuals (n 9) not diagnosed with prostate cancer. Values are shown asmean S.E. (error bars); *, p 0.05; **, p 0.01; ***, p 0.001; ns, not significant.
D, anti-GRP78 AutoAb titers are significantly lower in prostate cancer patients after (24 weeks postoperative) versus before prostatectomy (90.88g/ml versus
124.2 g/ml; ***, p 0.0001).
Anti-GRP78 AutoAbs potentiate prostate cancer growth via TF
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Results
GRP78 levels correlate with prostate cancer grade
Previous studies by Pootrakul et al. (26) and Daneshmand et
al. (27) demonstrated a link between GRP78 expression and
disease stage in a large patient cohort diagnosed with prostate
cancer. To confirm GRP78 expression during prostate cancer
progression, we have exploited the Human Protein Atlas (28), a
tissue-based immunohistochemical (IHC) map of the human
proteome. The reported samples can be pathologically classi-
fied following the Gleason scoring system (29) as follows: not
otherwise specified  grade 1; low grade  grade 2; high
grade  grade 4. Fig. 1A (top) shows low-level staining for
GRP78 in grade 1 prostate cancer. In grade 2 prostate cancer
(middle), GRP78 expression increases in most tumor cells.
Finally, in grade 4 prostate cancer (bottom), there is a strong
immunostaining for GRP78. Both cytoplasmic and membra-
nous positivity for GRP78 are reported for these index samples
in the Human Protein Atlas. These findings suggest that
increased amounts of total GRP78, paralleled by cell-surface
relocation of the protein (9), correlate with the progression of
human prostate cancer, consistent with our previous report
(15).
AutoAb titers against csGRP78 increase with serum PSA
concentration in patients with prostate cancer
Having shown thatGRP78 expression increaseswith grade in
human prostate cancer (Fig. 1A), we next evaluated the circu-
lating pool of anti-GRP78 AutoAbs in a panel of serum samples
(n  48) from prostate cancer patients (Ontario Tumor Bank,
Ontario, Canada). Utilizing an established ELISA protocol (25),
we showed that anti-GRP78 AutoAb titers increase with serum
concentrations of PSA, a marker that has been proposed as a
surrogate for prostate cancer grade (30) (Fig. 1B, Pearson cor-
relation test; p 0.05, r 0.38). Although the correlation was
considered modest, it is statistically significant for this small
number of samples. Thus, a larger cohort of patients will be
further investigated. Based on this, we classified the patient-
derived samples based on their serum PSA concentrations as
low (1–2 ng/ml), medium (3–7 ng/ml), high (8–19 ng/ml), and
very high (20 ng/ml), following theD’Amico clinical standard
in prostate cancer risk categories (31). Age-matched, prostate
cancer–free men served as negative controls. This analysis
demonstrated that the anti-GRP78 AutoAb response is pro-
gressively amplified with the increase in serum PSA concentra-
tions, with the patient cohort having markedly higher anti-
GRP78 AutoAb titers than the control cohort (Fig. 1C).
Because the half-life of circulating antibodies is generally less
than 3weeks, a sustained and consistent antigen presentation is
required to achieve functional levels of antigen-specific IgG-
type responses (32). To evaluate whether a similar mechanism
takes place in the case of anti-GRP78 AutoAbs, we evaluated
a selected cohort of prostate cancer patients. Two patient
cohorts treated with radical prostatectomywere examined pre-
operatively (cohort 1) and 24 weeks postoperatively (cohort 2)
for their anti-GRP78 AutoAbs titers (Fig. 1D). Consistently
with this working hypothesis, we found a significant decrease in
anti-GRP78 AutoAb titers in patients after surgical resection of
Figure 2. Treatment with anti-GRP78 AutoAbs increases the expression
of TF and UPR markers in DU145 human prostate cancer cells. A, flow
cytometry analysis of csGRP78 amounts in DU145 cells. B, pathological doses
of anti-GRP78AutoAbs (60g/ml) increase protein expression of both TF and
markers of UPR activation (PDI, IRE1, and phospho-eIF2), compared with
non-treated (0 g/ml) cells or cells treated with a normal dose of anti-GRP78
AutoAbs (5g/ml).-Actin was used as a loading control. C, protein bands of
the immunoblot in B were quantified with ImageJ, and values were normal-
ized to-actin. Error bars are S.D. p-eIF2, phosphorylation of the initiation
factor eIF2.D, quantitative real-timePCRanalysis ofGRP78andsplicedXBP1
mRNA expression in DU145 cells treated with a pathological dose of anti-
GRP78 AutoAbs (60 g/ml). Results are expressed as -fold induction over
non-treated (NT) cells (*, p 0.05; n 3). E, pathological doses of anti-GRP78
AutoAbs (60 g/ml) do not increase GRP78 expression in PC-3 cells; thapsi-
gargin (Tg; 300 nM) or tunicamycin (Tm; 2.5g/ml) was used as a control UPR
inducer. -Actin was used as a loading control.
Anti-GRP78 AutoAbs potentiate prostate cancer growth via TF
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the primary tumor (cohort 1) compared with preoperative lev-
els (cohort 2) (t test, p  0.0001). To date, these postoperative
patients (cohort 2) have undetectable serum PSA concentra-
tions (PSA  1 ng/ml; data not shown) and are in clinical
remission.
Binding of anti-GRP78 AutoAbs to csGRP78 activates the UPR
Recently, we showed that binding of anti-GRP78 AutoAbs to
csGRP78 results inCa2 efflux from the ER andUPR activation,
a pro-survival pathway initiated by ER stress (25). Here, we first
confirmed the presence of csGRP78 in the prostate cancer cell
line DU145 by flow cytometry (Fig. 2A). Treatment of DU145
cells with pathological (i.e. found in prostate cancer patient
sera) concentrations (60 g/ml) of anti-GRP78 AutoAbs
induced expression of UPR markers at both the protein (Fig. 2,
B and C) and RNA levels (Fig. 2D). This included increased
expression of the protein-disulfide isomerase (PDI), inositol-
requiring enzyme-1 (IRE1), phosphorylation of the initiation
factor eIF2 (p-eIF2), and spliced X-box-binding protein-1
(sXBP1). In contrast, expression of CCAAT/enhancer-binding
protein (C/EBP) homologous protein (CHOP), an apoptosis
marker, did not change in response to anti-GRP78 AutoAbs
(Fig. 2, B and C), data indicative of response specificity. Remark-
ably,mRNA levels ofGRP78 itself are increased5-fold upon cell
treatment with the AutoAbs (Fig. 2C), suggesting a positive
activation feedback loop in cancer cells. As a control, PC-3 cells
were treated with a pathological concentration of anti-GRP78
autoantibodies (60 g/ml). Different from the DU145 cell line,
the PC-3 cell line expresses a negligible amount of csGRP78 (25,
22). Unlike thapsigargin and tunicamycin, anti-GRP78 autoan-
tibodies fail to increase GRP78 and TF expression in the PC-3
cell line (Fig. 2E). Collectively, these findings suggest that UPR
induction is a reliable surrogate marker to establish a link
between anti-GRP78AutoAbs and csGRP78 in human prostate
cancer cells.
Tumor growth induced by anti-GRP78 AutoAbs requires TF
In previous work, de Ridder et al. (33) established that the
humoral response against csGRP78 promotes tumor growth
and proliferation. Further, we and others have demonstrated
that treating human prostate cancer cells with anti-GRP78
AutoAbs increases TF expression and activation, thereby pro-
moting cell proliferation (25, 34). Given these foundational
reports, we evaluated whether anti-GRP78 AutoAbs would
stimulate tumor growth in vivo. DU145 prostate cancer cells
were subcutaneously implanted into the flank of non-obese dia-
betic/severe combined immunodeficiency (NOD/SCID) mice.
Animals were administered at the site of the tumor with (i)
vehicle only (PBS), (ii) negative control antibodies (human
Figure 3. Anti-GRP78 AutoAbs accelerate tumor growth in mice and
increase protein expression of TF andUPRmarkers. A, treatment of NOD/
SCID mice bearing DU145 xenografts with anti-GRP78 AutoAbs (60 g/ml)
significantly increases tumor growth compared with PBS-treated or human
IgG-treated (60 g/ml) mice (*, p  0.05; **, p  0.001 versus IgG and PBS
treatment; n 8/group). Mean tumor volume S.E. (error bars) is shown. B,
IHC analysis of tumors from mice treated with anti-GRP78 AutoAbs demon-
strates an increase in TF expression compared with human IgG treatment.
Scale bar, 100m. C, quantitative real-time PCR analysis of tumors frommice
treated with anti-GRP78 AutoAbs demonstrates increased mRNA expression
of TF, VEGR, Ki67, spliced XBP1, ATF4, and GRP78 (*, p 0.05 versus IgG treat-
ment; n  3). D, gene expression levels of seven UPR markers (derived by
NanoString) following treatment with control human IgG (60 g/ml) or
anti-GRP78 AutoAbs (60 g/ml). p values are indicated for each gene (n
3/treatment). E, IHC analysis of the proliferationmarker Ki67 demonstrates
an increase in positive cells in the anti-GRP78 AutoAb-treated group com-
pared with control human IgG. Representative images of five sections are
shown. ImageJ was used to count the number of Ki67-positive cells. Scale
bar, 100 m.
Anti-GRP78 AutoAbs potentiate prostate cancer growth via TF
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IgG), or (iii) anti-GRP78 AutoAbs. Six weeks post-administra-
tion, animals treated with anti-GRP78 AutoAbs showed mark-
edly larger tumors compared with both vehicle– and human
IgG control–treated groups (Fig. 3A). This accelerated tumor
growth became even more pronounced at week 8, when the
experiment was terminated. In parallel, tumor expression of TF
protein increased upon treatment with anti-GRP78 AutoAbs,
compared with human IgG treatment (Fig. 3B), consistent with
a similar increase in TF mRNA levels (Fig. 3C). As observed in
vitro for DU145 prostate cancer cells, tumor xenografts from
mice treated with anti-GRP78AutoAbs expressed substantially
higher levels of GRP78 and other UPRmarkers, such as activat-
ing transcription factor-4 (ATF4) and sXBP1, along with the
proliferation marker Ki67 and the angiogenic marker vascular
endothelial growth factor receptor-2 (VEGFR2), compared
with control-treatedmice (Fig. 3C). Consistent with these find-
ings, gene expression analysis by usingNanoString technology
identified numerous UPR genes in addition to GRP78, including
the protein kinase RNA-like endoplasmic reticulum kinase
(PERK), calnexin, calreticulin, ATF4, ATF6, and total XBP1 that
were clearly up-regulated in xenografts from mice treated with
anti-GRP78 AutoAbs (Fig. 3D and supplemental Fig. 1). We
observed a 48% increase in proliferating (Ki67-positive) cells in
xenografts exposed to anti-GRP78 AutoAbs (n  1309, 72.54-
pixel2 average cell area) compared with those exposed to human
IgG control (n 676, 60.09-pixel2 average cell area) (Fig. 3E).
We next evaluated whether TF would directly mediate the
effect of anti-GRP78 AutoAbs on increased tumor progression
Figure 4. TF downmodulation in DU145 cells inhibits anti-GRP78 AutoAb-mediated TF activity and tumor progression. A, Western blot analysis of TF
expression in cells transduced with lentiviral particles encoding TF shRNA. Control cells were transduced with lentiviral particles encoding GFP (DU145GFP).
-Actin was used as a loading control. Clone 4 demonstrates high efficiency of TF knockdown (DU145KD). B, TF procoagulant (PCA) activity is induced by the
anti-GRP78AutoAbs and is proportional to TF expression levels (*,p0.05AutoAbs () versusnon-treated () cells;n5).C, in vivo, DU145KD xenografts grow
more slowly than DU145GFP xenografts (*, p 0.05).D, IHC analysis demonstrates lower TF expression in DU145KD xenografts, comparedwith DU145GFP (left);
TF total protein amounts were lower in the DU145 TFKD animal group versus control (Western blotting; right). Scale bar, 100 m. Mean tumor volume S.D.
(error bars) is shown. E, anti-GRP78 AutoAb treatment (60 g/ml) does not alter the rate of tumor growth in DU145KD xenografts. Human IgG (60 g/ml)
treatmentwasusedas a control (n5/group).Mean tumor volumesS.D. are shown.ns, not significant. F, treatmentofDU145 cellswith Tg (5M), anti-GRP78
AutoAbs (60g/ml), or patient sera increases TF activity, whereas immunodepletion of anti-GRP78 AutoAbs prevents TF activity (*, p 0.05 versusNT cells; #,
p 0.05 versusAutoAb treatment; n 5/group).G, pretreatment of sera from prostate cancer patients with human recombinant GRP78 (hrGRP78) (60g/ml)
prevents the activation of TF in DU145 cells (*, p 0.05 versus NT cells; #, p 0.05 versus corresponding native serum; n 5/group).
Anti-GRP78 AutoAbs potentiate prostate cancer growth via TF
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by transducing DU145 prostate cancer cells with TF-targeted
shRNA lentiviral vectors. A lentiviral vector encoding the GFP
was used to produce the control DU145GFP cells. Western blot
analysis of four stable antibiotic-resistant (TF-silenced) clones
revealed variable decreases in TF protein expression (Fig. 4A),
with clone 4 showing undetectable levels of endogenous TF
(henceforth designated as DU145 knockdown, DU145KD).
Treatment with the anti-GRP78 AutoAbs increased TF
activity in DU145GFP and DU145 clone 1 (DU145#1; TF
expression reduced but still detectable), but, as expected
due to the absence of TF protein, not in in DU145KD cells
(Fig. 4B). A concentration-dependent response to GRP78
AutoAbs was noted when comparing DU145GFP (high TF
response), DU145 clone 1 (intermediate TF response), and
DU145KD (undetectable TF response), a result again indica-
tive of specificity (Fig. 4B).
We next examined the contribution of TF to tumor progres-
sion in xenografts obtained in NOD/SCID mice by implant of
either DU145GFP or DU145KD cells (5  105 cells/animal). In
this experiment, we used a smaller number of cells to allow for
longer monitoring period of these tumors. Six weeks post-ad-
ministration, DU145KD tumors were significantly smaller than
control DU145GFP tumors (Fig. 4C). Immunostaining showed
decreased TF expression in DU145KD tumors compared with
DU145GFP tumors (Fig. 4D) and confirmed that TF presence
and activity are necessary for tumor growth. To define the con-
tribution of TF to tumor growth mediated by anti-GRP78
AutoAbs, DU145KD cells were implanted in NOD/SCID mice.
Because these xenografts grow relatively slowly (Fig. 4C), in
these experiments, we implanted higher numbers of human
prostate cancer cells (1  106/animal). This step was imple-
mented to maintain consistency with in vivo experiments by
using parental DU145 cells. Animals were randomized in
two cohorts that received a weekly administration of either
anti-GRP78 AutoAbs or human IgG control at the tumor
site. We observed no differences in tumor growth between
the anti-GRP78 AutoAb-treated cohort and the human IgG
control cohort (Fig. 4E). These findings demonstrate that the
tumor growth induction triggered by anti-GRP78 AutoAbs
(Fig. 4C) is TF-dependent.
Figure 5. Heparin and enoxaparin prevent the binding of anti-GRP78 AutoAbs to DU145 cells and inhibit tumor growth. A, heparin pretreatment (50
IU/ml) inhibits the effect of anti-GRP78AutoAbs on TF activation, whereas it does not affect TF activity on non-treated (NT) or Tg-induced (5M) DU145 cells (*,
p  0.05 versus NT; #, p  0.05 versus treatment with anti-GRP78 AutoAbs; n  5/group). B, heparin (50–100 IU/ml) and enoxaparin (5–40 mg/ml) prevent
anti-GRP78 AutoAb-mediated activation of TF in DU145 cells (*, p 0.05 versusNT cells; #, p 0.05 versus AutoAb treatment; n 5/group). C, GRP78 binding
and immunostaining (green) by anti-GRP78 AutoAbs on intact DU145 cells (left image) is abolished by pretreating cells with heparin (10 IU/ml;middle image)
and enoxaparin (50g/ml; right image). DAPI was used to stain the nuclei (blue). Scale bar, 20m. D, NOD/SCIDmice bearing DU145 xenografts were treated
witheither anti-GRP78AutoAbs (60g/ml) or human IgG (60g/ml, control), followedbya secondary treatmentwitheither enoxaparin (6mg/kg/week) or PBS
(control). The observed potentiation of tumor growth by the anti-GRP78 AutoAbs (**, p  0.001 versus IgG, n  6/group, left) is abrogated by a secondary
treatment with enoxaparin (n 6/group, right). At week 6, all mice receiving anti-GRP78 AutoAb/PBS treatment reached the end point. ns, not significant. E,
gene expression levels of seven UPR markers (derived by NanoString) following treatment with control human IgG (60 g/ml) or anti-GRP78 AutoAbs (60
g/ml), followed by enoxaparin (6 mg/kg/week) treatment. p values are indicated for each gene; n 3/treatment.
Anti-GRP78 AutoAbs potentiate prostate cancer growth via TF
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Immunodepletion or neutralization of anti-GRP78 AutoAbs
inhibits TF activity
Because binding of purified anti-GRP78 AutoAbs to csGRP78
increases TF expression (Fig. 3, B and C) and activity (Fig. 5B),
we next evaluated the specificity of this mechanism in serum
samples from prostate cancer patients. TF procoagulant activ-
ity was substantially increased in cultured DU145 cells treated
with either purified anti-GRP78 AutoAbs (60 g/ml) or undi-
luted patient sera containing 60g/ml of anti-GRP78 AutoAbs
(Fig. 4F), but not in sera that was immunodepleted of anti-
GRP78 AutoAbs as described (25). Thapsigargin was used as a
positive control (25) due to its inherent ability to increase cyto-
solic Ca2 concentration and to activate TF (Fig. 4F). In addi-
tion, neutralization of the anti-GRP78 AutoAb pool by pre-
treatment of patient sera with human recombinant GRP78
(hrGRP78, 60 g/ml) clearly reduced TF activation, data indic-
ative of specificity. Together, these findings demonstrate that
circulating anti-GRP78 AutoAbs are predominant activators of
TF in serum samples of prostate cancer patients, which seem to
contain no additional factors which can enhance TF activity.
Unfractionated heparin and LMWHblock the binding of
anti-GRP78 AutoAbs to csGRP78 and reduce tumor
growth in vivo
Previous studies have shown that GRP78 possesses a hepa-
rin-binding domain spanning residues Leu98–Thr102 (35) that
is coincident with the epitope recognized by the anti-GRP78
AutoAbs (12). We therefore examined whether heparin could
compete for the binding of anti-GRP78 AutoAbs to csGRP78.
Pretreatment ofDU145 cellswith heparin (50 IU/ml) prevented
activation of TF by the anti-GRP78 AutoAbs but did not affect
thapsigargin-induced TF activity (Fig. 5A). In addition to stan-
dard (unfractionated) heparin, we also examined a LMWH,
enoxaparin, confirming a similar inhibition of anti-GRP78
AutoAb-induced TF activation (Fig. 5B). Furthermore, DU145
cells pretreated with enoxaparin showed markedly lower bind-
ing of anti-GRP78 AutoAbs to csGRP78, as demonstrated by
fluorescence imaging, compared with untreated cells (Fig. 5C).
Based on these observations, we examined the ability of enoxa-
parin to counteract the tumor progression effects of anti-
GRP78 AutoAbs in vivo. Immunodeficient mice were xeno-
grafted with DU145 prostate cancer cells, followed by weekly
administration of either anti-GRP78 AutoAbs or control
human IgG at the tumor site. One week after the first AutoAb
treatment, mice received either enoxaparin (6 mg/kg/week) or
PBS (control). As expected, animals treated with anti-GRP78
AutoAbs exhibited significantly larger tumors compared with
control IgG-treated animals (Fig. 5D, left). In contrast, mice in
the enoxaparin-treated group were unresponsive to the anti-
GRP78 AutoAbs; the observed, slow tumor growth was not dif-
ferent in PBS-treated mice (Fig. 5D, right). We concluded that
enoxaparin treatment blocks the portion of tumor growth elic-
ited by anti-GRP78 AutoAb, whereas it does not possess inher-
ent anti-tumor properties in vivo, at least in this experimental
xenograft mouse model.
Finally, gene expression was assessed with NanoString in
tumors from mice treated with either anti-GRP78 AutoAbs or
human IgG control followed by enoxaparin. This analysis
showed no consistent difference in the induction of UPR genes
(Fig. 5E and supplemental Fig. 1). These findings indicate that
enoxaparin abolishes the effect of anti-GRP78AutoAbs onUPR
activation mediated via csGRP78 (compare with Fig. 3D and
supplemental Fig. 1).
Discussion
In this study, we present data that support an intriguing and
unique role for anti-GRP78 AutoAbs as potentiators of human
prostate cancer cell proliferation in vitro and tumor growth in
vivo, using the DU145 model cell line. By using experimental
cell culture,mousemodels, and clinical samples, we consistent-
ly demonstrate a functional role of anti-GRP78 AutoAbs as a
determinant of prostate cancer progression. Mechanistically,
anti-GRP78 AutoAbs purified from serum samples of prostate
cancer patients target GRP78 on tumor cell surfaces, triggering
an increased expression and activation of TF, a mediator of
tumor proliferation. This effect is evidently specific, as either
immunodepleting or neutralizing these AutoAbs revealed no
other factor in the serum of prostate cancer patients capable of
inducing TF expression or activity. Moreover, we demonstrate
for the first time that anti-GRP78 AutoAbs directed (largely or
exclusively) against the Leu98–Leu115 epitope within the N-ter-
minal domain of GRP78 markedly increase TF-dependent
tumor growth. Perhapsmost strikingly, the LMWHenoxaparin
reverts this anti-GRP78 AutoAb-induced potentiation of
tumor growth but otherwise has no anti-tumor effect. Taken
together, the results presented here support a working model
(Fig. 6) whereby TF activation via binding of anti-GRP78 Auto-
Abs to GRP78 on the cancer cell surface represents a critical
mechanistic switch for tumor growth and, therefore, a potential
target pathway for therapeutic intervention.
GRP78 has long been recognized as a stress-response molec-
ular chaperone that is instrumental in the folding and assembly
of newly synthesized proteins within the ER (36). In addition,
GRP78 redirectsmisfolded proteins for ER-associated degrada-
tion, regulates ionized Ca2 homeostasis, and controls the acti-
vation of the UPR following ER stress. However, a wide range of
human tumor cell lines show that GRP78 can function in a
manner distinct from its well-established chaperone activity. In
fact, a large body of work has recently revealed that GRP78may
associate with the cell surface (“protein moonlighting”) (9)
under stress conditions, such as cancer, to function as a modu-
lator of signal transduction in cell proliferation, tumor invasion,
and immunity (5, 10). A humoral response against csGRP78
correlates with poor prognosis in patients with prostate cancer
(12), and anti-GRP78 AutoAbs from prostate cancer patients
exhibit mitogenic potential on various human prostate cancer
cell lines, including 1-LN andDU145 (22). These findings imply
that the AutoAb response directed against csGRP78 represents
not only a candidate marker of disease progression but also a
functional element for tumor cell proliferation and prostate
cancer growth. Although recent studies suggest that immunity
against GRP78 accelerates tumor growth in vivo (33), the direct
contribution of these particular anti-GRP78AutoAbs, aswell as
the underlying mechanism(s) of this enhanced tumorigenicity,
have not as yet been fully defined.
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By using archived tumor tissue and serum samples from an
annotated patient cohort diagnosed with different stages of
prostate cancer, we demonstrated a substantial increase in
GRP78 in more advanced disease. Further, there was a positive
correlation between serum PSA concentration levels and anti-
GRP78 AutoAb titers in a subset of prostate cancer patients
having advanced disease before receiving surgical treatment.
Circulating anti-GRP78 AutoAbs have also been reported in
other cancers, including colorectal (37), hepatocellular (38),
and ovarian carcinomas (18, 39); however, the humoral im-
mune response against csGRP78 in human prostate cancer
appears to be notably striking compared with other malignant
solid tumors (12). Thus, the presence of circulating anti-GRP78
AutoAbs in the blood of cancer patients should now be consid-
ered as a candidate serological marker for early prostate cancer
detection (12, 40).
It is well-documented that an increase in antigen presenta-
tion on the surface of cancer cells can drive antibody produc-
tion (32). Thus, we compared anti-GRP78 AutoAb titers in the
pre-prostatectomy setting (patients with active prostate can-
cer) with the post-prostatectomy setting (prostate cancer
patients deemed to have no evidence of disease). Postoperative
patients demonstrated much lower levels of anti-GRP78 Auto-
Abs compared with preoperative patients. This finding sup-
ports the concept that the expression of GRP78 on the surface
of prostate cancer cells induces an anti-GRP78 AutoAb
response. Whereas postoperative patients had significantly
lower anti-GRP78 AutoAb titers compared with patients with
active disease, these titers were not reduced to the levels
observed in the control cohort of non-prostate cancer patients.
We are currently investigating whether anti-GRP78 AutoAb
titers would eventually return to normal levels over time in
patients undergoing radical prostatectomies as primary surgi-
cal management of prostate cancer with curative intent; if so,
one might speculate that the anti-GRP78 circulating titers
could serve as an early humoral warning of disease progression
and/or tumor recurrence.
The correlation of anti-GRP78AutoAbswith prostate cancer
grade suggests a potential contributory role in mediating dis-
ease progression.We examined themechanisms bywhich anti-
GRP78 AutoAbs enhance prostate cancer cell survival and
tumor growth. We have previously shown that the binding of
anti-GRP78AutoAbs to csGRP78 depleted ERCa2 stores (25).
This process is necessary to activate theUPR pro-survival path-
way (24). Interestingly, the high concentrations of anti-GRP78
AutoAbs observed in patients with prostate cancer induced
several UPRmarkers at both the protein and RNA levels. How-
ever, therewas no change in the expression of the pro-apoptotic
marker CHOP, a bZIP transcription factor induced by the
ATF6 and PERK pathways (41), an observation internally con-
sistent with the system specificity. UPR activation enables cells
to either manage current stress conditions or activate apopto-
sis. Mild activation of the UPR leads to adaptation to cellular
stresses by means of increased chaperone expression, suggest-
ing a link with the selective intrinsic instabilities of apoptotic
proteins, such as CHOP, to create a strong pro-survival bias
(41). GRP78 expression is a hallmark of the UPR and has
recently been linked to chemo-resistance (42); therefore, we are
currently investigating whether UPR activation following the
specific binding of anti-GRP78 AutoAbs to csGRP78 might
indeed confer protection against apoptosis and contribute to
tumor growth and metastasis.
We have previously elucidated the mechanism by which
binding of anti-GRP78 AutoAbs to csGRP78 increases TF
expression and activity (25). It is worth noting that, althoughTF
and GRP78 are expressed on the cell surface, the interaction
between the two proteins is casual at best (6), supporting an
indirect mechanism of TF induction. Further, it is well-estab-
Figure 6. Summary model. Anti-GRP78 AutoAbs increase tumor growth by binding to cell-surface GRP78 and activating TF. This interaction can be inter-
ruptedby treatmentwithheparinor enoxaparin. Bindingof anti-GRP78AutoAbs to cell-surfaceGRP78 induces elevated cytosolic Ca2 concentrations that can
activate thepro-survivalUPRpathwayand increaseTFactivity.Overall, this interaction leads toan increased rateof tumorgrowth, improvedangiogenesis, and,
potentially, enhanced survival via UPR activation.
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lished that TF expression and activation correlate with
increased tumor progression (3). In addition to the risk of
thrombosis among cancer patients (43), TF has long been rec-
ognized to increase inflammation, angiogenesis, and tumor
proliferative capacity (3). Based on this background, we moni-
tored tumor growth in an in vivo model system, the immuno-
deficient NOD/SCID mice, that allows the growth of human
tumor xenografts in the presence of a complete repertoire of
coagulation factors (44). Studies showed that tumors derived
from wild-type DU145 prostate cancer cells, but not DU145
cells with silenced TF expression, responded with enhanced
tumor growth upon anti-GRP78 AutoAb treatment. Consis-
tently, AutoAb-treated tumors showed UPR activation and
increased levels of Ki67 and VEGFR2. These findings indicate
that other pathways that influence tumor and stromal cell pro-
liferation and viability are activated following binding of anti-
GRP78 AutoAbs to target csGRP78.
ImpairedTF expression and/or function can potentially limit
tumor progression; however, direct modification of TF expres-
sion is challenging, given the inherent risk of coagulopathy
induction in clinical settings (45). Instead, here we have
explored alternative approaches to block the interaction of
anti-GRP78 AutoAbs with csGRP78 on prostate cancer cells.
Previous studies reported that GRP78 contains a heparin-bind-
ing site consisting of Leu98–Thr102 (35), which resides within
the N-terminal region of GRP78 known to contain the epitope
for anti-GRP78 AutoAb binding (22). Although heparin and
enoxaparin could function as anti-cancer agents, the underly-
ing molecular mechanisms have not been fully characterized
(46). The in vitro data presented here show that heparin and
LMWH are sufficient to disrupt the binding of anti-GRP78
AutoAbs to csGRP78 and to reduce TF activity commensu-
rately. Heparin treatment did not affect the induction of TF
activity by thapsigargin (data not shown), indicating that hepa-
rin does not inhibit the release of ER Ca2 that contributes to
TF activation (25). In addition, we have demonstrated that
enoxaparin pretreatment inhibited anti-GRP78 AutoAbs bind-
ing to the surface of DU145 cells. Together, these data indicate
that heparin/enoxaparin can successfully inhibit TF activity by
counteracting the effect of anti-GRP78 AutoAbs. These find-
ings also provide an innovative mechanism by which heparin
reduces local anticoagulant effects independent of its ability to
inactivate thrombin and Xa via antithrombin.
Finally, we designed an interventional study to begin to assess
the ability of enoxaparin to block the growth of DU145 xeno-
grafts in the presence or absence of anti-GRP78AutoAbs and in
an animal model (NOD/SCIDmice) in which a complete coag-
ulation system is present. Treatment with enoxaparin abol-
ished the effect of anti-GRP78AutoAbs on accelerated prostate
cancer growth in these tumor-bearingmice. Consistently, anal-
ysis of tumors treated with anti-GRP78 AutoAbs and enoxa-
parin demonstrated no UPR activation, compared with tumors
treated only with anti-GRP78 AutoAbs. Our studies suggest
that LMWH agents such as enoxaparin, which can interfere
with AutoAb targeting of csGRP78, might well comprise a
unique therapeutic strategy to treat prostate cancer and per-
haps other human tumors that induce anti-GRP78 humoral
responses. Of course, the potential benefits of enoxaparin or
heparin as a therapeutic intervention in this setting must be
carefully balanced against the bleeding risk in translational clin-
ical trials.
In summary, the results presented here uncover an unrecog-
nized molecular mechanism by which anti-GRP78 AutoAbs
drive TF-mediated tumor progression in the setting of prostate
cancer. Furthermore, these findings also suggest a translational
approach to treat prostate cancer with either heparin or hepa-
rin-likemolecules in prostate cancer patients with elevated lev-
els of circulating anti-GRP78 AutoAbs.
Experimental procedures
Cell culture and recombinant proteins
Tumor cell lines were purchased from the American Type
Culture Collection (Manassas, VA). The human prostate can-
cer cell line, DU145, was cultured in minimum essential
medium plus GLUTAMAXTM (Invitrogen). Media were sup-
plemented with 10% FBS (Sigma-Aldrich) containing 100
units/ml penicillin and 100 g/ml streptomycin (Invitrogen).
Cellsweremaintained at 37 °C in a humidified atmosphere con-
taining 5% CO2. Thapsigargin (Sigma-Aldrich, Oakville, Can-
ada) was used as a positive control for the TF activity assay.
Stock solutions were prepared in DMSO and diluted in physi-
ological buffer to achieve a final concentration of 5M. Human
recombinant GRP78 was resuspended at 60 g/ml in PBS and
used to neutralize anti-GRP78 AutoAbs.
Human Protein Atlas
Representative images of prostate adenocarcinoma, not
otherwise specified (M-81403, patient ID 3040), low-grade
(M-814031, patient ID 3957), and high-grade (M-814033,
patient ID 3978) were downloaded from the publicly available
database of the Human Protein Atlas (http://www.proteinatlas.
org)3 and were analyzed for total and surface-associated
GRP78. Prostate cancer was graded in these samples by pathol-
ogists, and a grade from 1 to 5was assigned based on themicro-
scopic resemblance between the cancerous cells and normal
prostate tissue.
Serum PSA concentration and anti-GRP78 AutoAb titers
Human specimens were obtained from the Ontario Tumor
Bank, Ontario Institute for Cancer Research. Blood samples
were taken from a cohort of patients diagnosed with prostate
cancer before treatment administration. Serum PSA concen-
trations were provided by the Ontario Tumor Bank. Anti-
GRP78 AutoAb titers were measured with an established
ELISA protocol as described (25).
Isolation of anti-GRP78 AutoAbs from patient samples
A study by Mintz et al. (12) has identified the CNVSDKSC
peptide that resembles the N-terminal domain of GRP78. Pos-
itive serum reactivity to the CNVSDKSC peptide was specifi-
cally linked to disease progression and shorter survival in a large
patient population (12). Blood samples and corresponding sera
frompatients (n 24) with prostate cancer were obtained from
3 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
Anti-GRP78 AutoAbs potentiate prostate cancer growth via TF
21188 J. Biol. Chem. (2017) 292(51) 21180–21192
 at Biblioteche biom
ediche U
niversita' di Torino on January 19, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
the Department of Urology, St. Joseph’s Healthcare Hamilton
(Hamilton, Canada). Written informed consent was obtained
from each patient and approved by the Research Ethics Board
of St. Joseph’s Healthcare Hamilton (approval 08-3047). Anti-
GRP78 AutoAbs were purified by affinity against the N-termi-
nal region of GRP78 (Leu98–Leu115) (25). Briefly, a conforma-
tional peptide, CNVSDKSC, mimicking the 3D domain of
Leu98–Leu115 of GRP78 was synthesized (CanPeptide Inc.,
Pointe-Claire, Canada) and immobilized on a Sepharose A col-
umn (SulfoLink protein kit, catalog no. 44995, ThermoFisher).
Patient sera were incubated with the immobilized conforma-
tional peptide columns and eluted as per the manufacturer’s
instructions. Eluted fractions were dialyzed with PBS, concen-
trated using the AmiconUltra 15 centrifugal filters, stored 4 °C,
and admixed to produce a pooled source of anti-GRP78 Auto-
Abs used for treatment. It is worth noting that the established
60 g/ml pathological dose of anti-GRP78 AutoAbs was first
reported by Gonzalez-Gronow et al. (22), in which anti-GRP78
AutoAb titers were analyzed in a prostate cancer patient cohort
in comparison with cancer-free, age-matched control patients.
This study reported an average anti-GRP78 AutoAb titer of 60
g/ml in prostate cancer patients compared with 1 order of
magnitude less (i.e. 5–7 g/ml) in the control group.
Immunoblotting
Tumor cells were lysed in denaturing sample buffer, and total
proteins were separated on a 10% SDS-polyacrylamide gel
under reducing conditions. Following separation, proteins
were transferred to nitrocellulose membranes (Bio-Rad) with a
Trans-Blot semi-dry apparatus (Bio-Rad). Membranes were
blocked overnight in Tris-buffered saline plus 0.1% Tween 20
(TBST) containing 5% skim milk and subsequently incubated
with the following primary antibodies: anti-GRP78/Bip (catalog
no. 610979, BD Transduction), anti-phospho-eIF2 (catalog
no. 9721S, BD Transduction), anti-VEGF pathway sampler kit
(catalog no. 8696, Cell Signaling, Danvers, MA), anti-TF (cata-
log no. 4502, American Diagnostica, Stamford, CT), anti-
CHOP (catalog no. B3, Santa Cruz Biotechnology, Inc., Dallas,
TX) followed by the appropriate HRP-conjugated secondary
antibodies (Dako, Carpentaria, CA) diluted inTBST containing
1% skim milk. Signals were visualized with the Western Light-
ing chemiluminescence reagent (PerkinElmer Life Sciences)
and Kodak X-OMAT Blue XB-1 film (PerkinElmer Life Sci-
ences) in a Kodak X-OMAT 1000A processor (Mississauga,
Canada). To control for protein loading, immunoblots were
stripped and reprobed with anti--actin antibody (catalog no.
A544, Sigma-Aldrich). ImageJ was used for densitometric band
quantification using the watershed algorithm as described on
the National Institutes of Health website (27).
Continuousmeasurement of cell-surface TF procoagulant
activity
Wehave previously developed an assay for themeasurement
of TF procoagulant activity on intact tumor cells (47). Briefly,
cells were seeded into a 96-well tissue culture plate (10,000
cells/well) the day before the experiment. The culture media
were removed, and cells were washed once in TBS. A mixture
containing 1 nM human FVIIa, 30 nM human FX, 10 mM CaCl2,
and 0.4 mM chromogenic substrate S-2765 (Diapharma, West
Chester, OH) in TBS was added to each well. Following the
addition of the test agent diluted in TBS, the absorbance at 405
nmwasmeasured every 2min for 3 h at 37 °C. A standard curve
was generated in which 100 units of TF activity was defined as
the activity of 450 g (0.3 l) of human recombinant TF (as
determined by theAmericanDiagnostica ELISA).Vmaxwas cal-
culated with SoftMax Pro and used to determine the amount of
FXa generated per 10,000 cells (units/10,000 cells).
RNA isolation and real-time PCR
RNAwas isolated with theQiagen RNeasyMini kit (Qiagen),
and cDNA was synthesized with the Applied Biosystems high-
capacity cDNA reverse transcription kit (Applied Biosystems).
Real-time PCRs were carried out based on standard protocols
with the SYBR Green MasterMix (Applied Biosystems) using
gene-specific forwardand reverseprimers (supplementalTable1).
TF-silenced prostate cancer cells
DU145 cells grown to 50% confluence in a 12-well plate were
infected with lentiviral particles carrying a human TF-specific
shRNA sequence (Santa Cruz Biotechnology). After 48 h, colo-
nies were selected in media containing 5 g/ml puromycin
(Santa Cruz Biotechnology) and assessed for TF expression
(Western blotting) and activity (continuous assay) (47). As a
control, DU145 cells were infected with lentiviral particles con-
taining the GFP sequence only. Colonies of lentivirus-infected
cells were selected by incubation in puromycin-containing
media.
Mouse xenograft models of human prostate cancer
All experiments were approved and performed following the
guidelines of the McMaster University Research Ethics Board
as outlined in the Animal Utilization Protocol (Hamilton, Can-
ada). Mice had access to food and water ad libitum. To obtain
xenografts of human prostate cancer cells, DU145GFP or
DU145KD cells were included in 0.1 ml of MatrigelTM and
administered subcutaneously into the flanks of 7-week-old
NOD/SCID male mice (Jackson Laboratory); all mice were
implanted with 1 106 cells, except for in Fig. 4C, where mice
were implanted with 5  105 cells to allow for a longer moni-
toring period. Tumor formation was monitored daily andmea-
sured weekly. When tumors reached 5% of body weight, mice
were sacrificed and tumors were collected. Tumor volume
was determined based on the following equation: volume 
length width2 0.52.
Anti-GRP78 AutoAb treatment in vivo
Tumor-bearing mice were weight-matched and randomized
into treatment cohorts for weekly injections. Control human
IgG or anti-GRP78 AutoAb concentrations were calculated
based on a total blood volume of 2.2 ml as reported for this
mouse strain by Jackson Laboratory: 168 g [IgG or anti-
GRP78 AutoAb]/2.2 ml [blood] 76 g/ml. The animal study
was organized as follows: (i) PBS (0.1 ml), (ii) control human
IgG, or (iii) anti-GRP78AutoAbs (each 168g in 0.1ml of PBS).
Tumor formation was monitored daily and measured weekly.
When tumors reached 5% of normal body weight, mice were
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sacrificed, and tumors were collected and processed for mRNA
analysis. For the enoxaparin intervention study, the interven-
tion cohort (n  5) received an additional injection of enoxa-
parin sodium (Lovenox; Sanofi Aventis) diluted in 0.9% sterile
saline at a concentration of 1 mg/ml and administered intratu-
morally at 6 mg/kg/week. The control cohort (n  5) received
100 l of vehicle only (PBS).
RNA isolation and NanoString analysis
Total RNA was isolated from flash-frozen mouse tumor tis-
sues with the RNeasy lipid tissue minikit (catalog no. 74804,
Qiagen). For quality assurance, only RNA samples with anRNA
integrity number greater than 5 were used for NanoString
analysis. Data were normalized against seven housekeeping
genes, namely IPO8, GUSB, TBP, YWHAZ, ACTB, GAPDH,
and RPLP2. p values were corrected for multiple comparisons
with the Benjamin–Hochberg procedure by nSolverTM soft-
ware (NanoString Technologies, Seattle, WA), and heat maps
were produced with Java Treeview software (Seattle, WA).
Hierarchical gene clustering was performed by Euclidean dis-
tance and complete linkage analysis.
GRP78 immunofluorescence and analysis of csGRP78 by flow
cytometry
DU145 cells were grown in chamber slides. Upon 50% con-
fluence, cells were left untreated or treated with 50 g/ml
enoxaparin or 10 IU/ml of heparin for 4 h. Live cells were incu-
bated with either anti-GRP78 AutoAbs (60 g/ml) or PBS for
2 h. Cells were fixed in 4% paraformaldehyde, and anti-GRP78
AutoAbs were detected with the anti-humanAlexa488 second-
ary antibody (Molecular Probes). Nuclei were visualized by
DAPI (Sigma). Slides were imaged with an Olympus DSU
microscope. For flow cytometry analysis, DU145 cells were har-
vested in Accutase (Sigma) and incubated with minimum
essential medium supplemented with 30% FBS and 10 g/ml
purified human IgG (catalog no. I2511, Sigma) for 20 min at
4 °C. Cells were washed with ice-cold PBS, and 1  106-cell
aliquots were incubatedwith 1g of phycoerythrin-conjugated
human anti-GRP78 AutoAbs or phycoerythrin-conjugated iso-
type control for 40min at 4 °C in 100l of PBS containing 0.5%
BSA. After two washes, cells were resuspended in ice-cold PBS
for flow cytometry analysis (AccuriC6, BD Biosciences). Data
were analyzed by FlowJo version 10.0.8 (FlowJo LLC).
Immunohistochemical staining
Tissues from tumor-bearingmice were fixed in formalin and
paraffin-embedded. Four-micrometer sections were deparaf-
finized and blocked with 5% normal goat (for Ki67 staining) or
rabbit serum (for TF staining). Sections were incubated with
primary antibody for 1 h at room temperature, followed by
either goat anti-rabbit or rabbit anti-goat biotinylated second-
ary antibody (Vector Laboratories, Burlingame, CA) diluted
1:500 in 0.05 M Tris buffer, pH 7.5, for 30min and subsequently
streptavidin-HRP (Zymed Laboratories Inc.) diluted 1:20 for 5
min. Sectionswere developed inNova RedHRP substrate (Vec-
tor Laboratories) and counterstainedwith hematoxylin. ImageJ
software was used to determine the number of Ki67-positive
cells as described (48).
Statistics
GraphPad software (Prism version 6.07) was used to analyze
quantitative data. Correlation studies of clinical data were ana-
lyzed based on the Pearson correlation test. Significance of dif-
ferences between controls and treatments was determined by
analysis of variance. Upon finding significance with analysis of
variance, an unpaired Student’s t test was performed. p 0.05
was considered significant.
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SUPPLEMENTARY FIGURE LEGENDS 
 
SUPPLEMENTARY FIGURE 1. Complete heat maps of gene expression. Fold changes represent the changes in 
gene expression with control human IgG (60 µg/ml), or anti-GRP78 AutoAbs treatment (60 µg/ml). (left panel) Both 
groups received enoxaparin treatment (6 mg/Kg/week). (right panel) No additional treatments were administered. 
 
 
SUPPELEMTARY TABLE 1. Primers for quantitative RT-PCR. 
 
Human 
genes Forward primers (5'-3') Reverse primers (5'-3') 
ATF4 GGGACAGATTGGATGTTGGAGA ACCCAACAGGGCATCCAAGT 
GRP78 CATCACGCCGTCCTATGTCG CGTCAAAGACCGTGTTCTCG 
Ki67 GGGCCAATCCTGTCGCTTAAT GTTATGCGCTTGCGAACCT 
XBP1s CCGCAGCAGGTGCAGG GAGTCAATACCGCCAGAATCCA 
TF GCCAGGAGAAAGGGGAAT CAGTGCAATATAGCATTTGCAGTAGC 
VEGFR GAGGAGCAGTTACGGTCTGTG TCCTTTCCTTAGCTGACACTTGT 
β-Actin TCACCCACACTGTGCCCATCTACGA CAGCGGAACCGCTCATTGCCAATGG 
18S GGCCCTGTAATTGGAATGAGTC CCAAGATCCAACTACGAGCTT  
 
J 
 
 
 
 
 
 
 
 
Supplementary Figure 1Scale bar
-1
.9
1
-1
.2
7
-0
.6
4
 0
.0
0
 0
.6
4
 1
.2
7
 1
.9
1
Enoxaparin
Ig
G Au
to
Ab
Ig
G Au
to
Ab
Austin
Serena Marchiò, Renata Pasqualini, Wadih Arap, Bobby Shayegan and Richard C. 
V. Pizzo, Mark Crowther, Anil Kapoor, Janusz Rak, Gabriel Gyulay, Sara D'Angelo,
F. Collins, Jehonathan H. Pinthus, Mario Gonzalez-Gronow, Jen Hoogenes, Salvatore 
Ali A. Al-Hashimi, Paul Lebeau, Fadwa Majeed, Enio Polena, Sárka Lhotak, Celeste A.
tumor growth via tissue factor
associated chaperone GRP78 stimulate−Autoantibodies against the cell surface
doi: 10.1074/jbc.M117.799908 originally published online October 24, 2017
2017, 292:21180-21192.J. Biol. Chem. 
  
 10.1074/jbc.M117.799908Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
Supplemental material:
  
 http://www.jbc.org/content/suppl/2017/10/24/M117.799908.DC1
  
 http://www.jbc.org/content/292/51/21180.full.html#ref-list-1
This article cites 49 references, 15 of which can be accessed free at
 at Biblioteche biom
ediche U
niversita' di Torino on January 19, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
